Literature DB >> 16545664

AMISTAD trials: possible reasons for lack of success.

Michael V Cohen, James M Downey.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 16545664     DOI： 10.1016/j.jacc.2005.12.040

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  5 in total

1.  Adenosine receptor crossroads in sickle cell disease.

Authors:  Mark T Gladwin
Journal:  Nat Med       Date:  2011-01       Impact factor: 53.440

Review 2.  A state-of-the-art review of the current role of cardioprotective techniques in cardiac transplantation.

Authors:  Paul P Cullen; Steven S Tsui; Noel M Caplice; John A Hinchion
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-05-10

3.  Translation of TRO40303 from myocardial infarction models to demonstration of safety and tolerance in a randomized Phase I trial.

Authors:  Sophie Le Lamer; Stéphanie Paradis; Hidayat Rahmouni; Corinne Chaimbault; Magali Michaud; Marcel Culcasi; Jean Afxantidis; Mathilde Latreille; Patrick Berna; Alain Berdeaux; Sylvia Pietri; Didier Morin; Yves Donazzolo; Jean-Louis Abitbol; Rebacca M Pruss; Sophie Schaller
Journal:  J Transl Med       Date:  2014-02-07       Impact factor: 5.531

Review 4.  9th Hatter Biannual Meeting: position document on ischaemia/reperfusion injury, conditioning and the ten commandments of cardioprotection.

Authors:  R M Bell; H E Bøtker; R D Carr; S M Davidson; J M Downey; D P Dutka; G Heusch; B Ibanez; R Macallister; C Stoppe; M Ovize; A Redington; J M Walker; D M Yellon
Journal:  Basic Res Cardiol       Date:  2016-05-10       Impact factor: 17.165

5.  Does Disruption of Optic Atrophy-1 (OPA1) Contribute to Cell Death in HL-1 Cardiomyocytes Subjected to Lethal Ischemia-Reperfusion Injury?

Authors:  Andrew R Kulek; Vishnu V R Undyala; Anthony R Anzell; Sarita Raghunayakula; Lee Ann MacMillan-Crow; Thomas H Sanderson; Karin Przyklenk
Journal:  Cells       Date:  2022-09-30       Impact factor: 7.666
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.